Format

Send to

Choose Destination
Cancer Discov. 2015 Mar;5(3):228-30. doi: 10.1158/2159-8290.CD-15-0073.

From histones to ribosomes: a chromatin regulator tangoes with translation.

Author information

1
Center for Epigenetics, Van Andel Research Institute, Grand Rapids, Michigan. brian_strahl@med.unc.edu scott.rothbart@vai.org.
2
Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
3
Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. brian_strahl@med.unc.edu scott.rothbart@vai.org.

Abstract

Histone lysine methylation is a critical regulator of chromatin-templated processes such as gene transcription and DNA repair, and is dynamically controlled by enzymes that write and erase this posttranslational modification. Although histone methylation has been well studied, the functions of nonhistone lysine methylation and its regulatory enzymes, particularly outside the nucleus, are poorly defined. In this issue of Cancer Discovery, Van Rechem and colleagues shed light on a new role for the lysine demethylase KDM4A as a regulator of protein translation and identify a single-nucleotide polymorphism in the KDM4A gene as a candidate biomarker for mTOR inhibitor therapy.

PMID:
25749972
PMCID:
PMC4355909
DOI:
10.1158/2159-8290.CD-15-0073
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center